<i>N</i>-(HETERO)ARYL-2-IMIDAZOLINES: AN EMERGING PRIVILEGED MOTIF FOR CONTEMPORARY DRUG DESIGN

Authors

  • Mikhail Krasavin Institute of Chemistry, Saint Petersburg State University, 26 Universitetskii Ave., Petrodvorets 198504

DOI:

https://doi.org/10.1007/3725

Keywords:

cyclodehydration, imidazoline N-arylation, lead-like compounds, privileged structures

Abstract

The diverse biological activities of compounds containing N-(hetero)aryl-2-imidazoline moiety and methods to construct them are comprehensively reviewed for the first time. This intriguing non-flat, cyclic amidine motif clearly represents an emerging privileged structure.

Author Biography

Mikhail Krasavin, Institute of Chemistry, Saint Petersburg State University, 26 Universitetskii Ave., Petrodvorets 198504

Mikhail Krasavin is a Professor of synthetic organic and medicinal chemistry (www.krasavin-group.org) at Saint Petersburg State University (Russia). Prior to assuming this post in 2014, he spent over 10 years in positions of increasing responsibility in pharmaceutical industry (Millennium Pharmaceuticals, Abbott Bioresearch Center, ChemDiv, Inc.) , where he was involved in multiple drug discovery programs in the areas of oncology, metabolic disease, infectious disease and CNS disorders. In 2011-2013 Dr. Krasavin led an independent research group at Eskitis Institute for Drug Discovery (Griffith University) in Brisbane, Australia. Prof. Krasavin has authored more than 100 manuscripts, 8 patents, several book chapters and has consulted various drug discovery and development business entities. In 2016, he was elected a Professor of the Russian Academy of Sciences.

 

Downloads

Published

2017-04-13

Issue

Vol. 53 No. 3 (2017): Privileged heterocyclic scaffolds in chemical biology and drug discovery: synthesis and bioactivity

Section

Review Articles